Skip to main content
Livermore
Livermore
ZHEN

TG Therapeutics, Inc.

TGTX
Exchange
Nasdaq
Industry
Pharmaceutical Preparations
SEC CIK
0001001316

In the last 90 days, TG Therapeutics, Inc. insiders filed 0 open-market purchases and 1 sale; 430 institutions reported holding it in 13F filings for Q2 2026, worth $6.10B in total; no superinvestor holds it.

Holders of 5% or more of TGTX

Holders whose latest Schedule 13D or 13G filing reports 5% or more of TG Therapeutics, Inc., largest stake first. The change is against the holder's previous filing.

Holders of 5% or more of TGTX
HolderLatest formStakeChangeFirst filedLatest filingFiling
BlackRock, Inc.13G/A12.80%20.1M shares–Apr 30, 20251 filingApr 30, 2025SEC
State Street Corp13G5.10%8.10M shares+0.40 ppfrom 4.70%May 13, 20252 filingsNov 10, 2025SEC

Stakes are as of each holder's latest filing. Holders whose last filing was in the old format (before December 18, 2024) have no stake on record and are not listed, and after an acquisition or delisting holders usually stop filing.

13D and 13G filings

5 Schedule 13D and 13G filings on TG Therapeutics, Inc., newest first, including old-format filings without a stake.

Schedule 13D and 13G filings on TGTX
Filed (ET)FilerFormStakeChangeEvent dateFiling
Mar 27, 20261:34 PM ETVanguard Group Inc13G/A0.00%0 shares−10.01 ppfrom 10.01%Below 5%Mar 13, 2026SEC
Nov 10, 20258:58 AM ETState Street Corp13G5.10%8.10M shares+0.40 ppfrom 4.70%Sep 30, 2025SEC
May 13, 202512:23 PM ETState Street Corp13G4.70%7.43M sharesNewBelow 5%Mar 31, 2025SEC
Apr 30, 202512:45 PM ETBlackRock, Inc.13G/A12.80%20.1M shares–Mar 31, 2025SEC
Jan 8, 202511:29 AM ETVanguard Group Inc13G/A10.01%15.6M shares–Dec 31, 2024SEC

Form 144: proposed insider sales

Notices from officers, directors and other affiliates planning to sell TG Therapeutics, Inc. shares.

No Form 144 notices for TG Therapeutics, Inc. are on file.